Cellbion
Financials
Valuation Metrics
Cellbion's Market Cap is ₩1817B. At end of 2025 it was ₩3046B. Ranked #879 of 2,436 in KR market (top 36%), #408 of 1,649 on KOSDAQ (top 25%), #95 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 41%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 181.71B KRW | KR#879/2,436 Sec#95/234 |
| Revenue | 2.08B KRW | KR#2,387/2,436 Sec#216/234 |
| Net Income | -8.54B KRW | KR—/2,436 Sec—/234 |
| Total Assets | 32.38B KRW | KR#2,311/2,436 Sec#220/234 |
| Net Assets | 20.57B KRW | KR#2,274/2,436 Sec#215/234 |
| Employees | 43 | KR#2,086/2,436 Sec#190/234 |
| Value | ||
| P/B | 8.83x | KR#2,328/2,436 Sec#206/234 |
| P/S | 87.44x | KR#2,384/2,436 Sec#207/234 |
| FCF Yield | -3.86% | KR—/2,436 Sec—/234 |
| Profitability | ||
| ROE | -41.53% | KR#2,238/2,436 Sec#192/234 |
| ROA | -26.39% | KR#2,269/2,436 Sec#188/234 |
| Op. Margin | -434.87% | KR#2,372/2,436 Sec#206/234 |
| Revenue Growth | 27.72% | KR#514/2,436 Sec#50/234 |
| Financial Health | ||
| Debt Ratio | 157.41% | KR#1,287/2,436 Sec#145/234 |
| Total Debt | 1.45B KRW | KR#1,927/2,436 Sec#187/234 |
| FCF | -7.02B KRW | KR#1,596/2,436 Sec#130/234 |
| Cash | 1.99B KRW | KR#2,249/2,436 Sec#216/234 |
| Current Ratio | 11.95x | KR#76/2,436 Sec#21/234 |
| Performance | ||
| 1Y Return | -48.52% | KR#2,048/2,436 Sec#191/234 |
| 1M Return | -17.61% | KR#2,111/2,436 Sec#209/234 |
| From 52W High | -66.64% | KR#2,022/2,436 Sec#174/234 |
| 1Y MDD | -73.67% | KR#2,088/2,436 Sec#187/234 |
| Trading | ||
| Volume | 39,614 shares | KR#1,490/2,436 Sec#151/234 |
| Foreign Own. | 4.03% | KR—/2,436 Sec—/234 |
| Per Share | ||
| EPS | -666 KRW | KR—/2,436 Sec—/234 |
| BPS | 1,603 KRW | KR#2,135/2,436 Sec#186/234 |
Company Info
CellBion was established in 2010 with the aim of becoming a global leader in radiopharmaceuticals, and was listed on the KOSDAQ market in 2024. The company focuses on developing new anti-cancer drugs for precision medicine and targeted therapy, with Lu-177-DGUL currently under development. It produces generic specialty pharmaceuticals and operates a contract development and manufacturing organization (CDMO) business through its GMP-certified injectable vial manufacturing facility. CellBion delivers patient-specific precision anti-cancer therapy for PSMA protein-expressing prostate cancer, improving patient quality of life and advancing medical care. CellBion is headquartered in Jongno-gu, Seoul.